LexDanaLexDanabeta
Inventor

Roger D. Tung

Inventor
Lexington, MA, US

Overview

121→
Patents
1993–2020
Patent span
Chemistry
Primary field (CPC C)

Patents· 121 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C07DHeterocyclic compounds24%
A61KPreparations for medical, dental or toiletry purposes18%
C07BGeneral methods of organic chemistry12%
C07CAcyclic or carbocyclic compounds10%
C07KPeptides4%
Y02ATechnologies for adaptation to climate change3%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
C07HSugars1%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
PatentTitleYear
10,842,792Deuterated baricitinib202010,843,993Deuterated idebenone202010,759,721Deuterated CFTR potentiators202010,738,036Deuterated CFTR modulators202010,668,036Deuterated analogs of D-serine and uses thereof202010,532,9714-hydroxybutyric acid analogs202010,442,761Deuterated GFT-505201910,343,968Deuterated idebenone201910,335,413Substituted xanthine derivatives201910,196,384Deuterated CFTR modulators201910,040,7484-hydroxybutyric acid analogs201810,017,445Deuterated idebenone20189,944,635Deuterated pyrazino[2,1-a]isoquinoline compounds and methods of treatment using the same20189,931,343Deuterated baricitinib20189,918,987'Substituted xanthine derivatives'20189,868,976'Morphinan compounds'20189,840,463'Deuterated rigosertib'20179,815,763'4-hydroxybutyric acid analogs'20179,777,009'Deuterated ibrutinib'20179,708,277'Inhibitors of cholesterol ester transfer protein'20179,707,218'Derivatives of pyrazole-substituted amino-heteroaryl compounds'20179,540,367'Deuterated baricitinib'20179,492,457'Substituted xanthine derivatives'20169,493,463'Substituted xanthine derivatives'20169,422,295'Deuterated ibrutinib'20169,328,113'Substituted xanthine derivatives'20169,314,440'Morphinan compounds'20169,309,182'4-hydroxybutyric acid analogs'20169,273,009'Tetrahydronaphthalene derivatives'20169,260,432'Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds'20169,249,093'Deuterated rigosertib'20169,233,938'Inhibitors of cholesterol ester transfer protein'20169,206,179'Methods of use comprising deuterated pyrazino[2,1-a]isoquinolines'20159,199,986'Deuterated pyrazino[2,1-a]isoquinolines for the treatment of diseases and/or conditions'20159,181,190'Deuterated vercirnon'20159,145,390'Derivatives of pyrazole-substituted amino-heteroaryl compounds'20159,133,137'Derivatives of gefitinib'20159,107,922'Pyrimidinecarboxamide derivatives'20159,072,711'Morphinan compounds'20159,051,261'4-hydroxybutyric acid analogs'20159,045,453'Substituted dioxopiperidinyl phthalimide derivatives'20159,035,050'Substituted xanthine derivatives'20158,993,570'Substituted triazolo-pyridazine derivatives'20158,987,442'Deuterium-substituted xanthine derivatives and methods of use'20158,952,016'Substituted xanthine derivatives'20158,889,687'Deuterated pyrazinoisoquinoline compounds'20148,796,267'Oxazolidinone derivatives and methods of use'20148,759,394'4-hydroxybutyric acid analogs'20148,759,383'Inhibitors of cholesterol ester transfer protein'20148,748,450'Morphinan compounds'20148,609,673'Vandetanib derivatives'20138,575,221'Derivatives of dimethylcurcumin'20138,575,361'Tetrahydronaphthalene derivatives'20138,563,554'Deuterated pyrazinoisoquinoline compounds'20138,552,008'Deuterated 3-(dihydro-1H-pyrazolo[4,3-D]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use'20138,541,436'Morphinan compounds'20138,513,434'Tetrahydronaphthalene derivatives'20138,471,034'Niacin prodrugs and deuterated versions thereof'20138,461,197'4-hydroxybutyric acid analogs'20138,455,497'Inhibitors of aspartyl protease'20138,450,492'Deuterated benzo[D][1,3]-dioxol derivatives'20138,410,082'Fluorinated diaryl urea derivatives'20138,343,980'Quinazoles useful as modulators of ion channels'20138,343,950'Quinazoline derivatives and methods of treatment'20138,338,425'Heterocyclic kinase inhibitors'20128,314,141'Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease'20128,263,601'Deuterium substituted xanthine derivatives'20128,258,309'Azapeptide derivatives'20128,188,110'Morphinan compounds'20128,158,805'Azapeptide derivatives'20128,153,642'Quinazolines useful as modulators of ion channels'20127,973,049'Morphinan compounds'20117,932,235'Triazolyl tropane derivatives'20117,863,274'Deuterium enriched analogues of tadalafil as PDE5 inhibitors'20117,855,204'Derivatives of gefitinib'20107,713,983'Quinazolines useful as modulators of ion channels'20107,678,802'Quinazolines useful as modulators of ion channels'20107,678,914'Deuterated benzo[D][1,3]-dioxol derivatives'20107,608,632'Sulfonamide inhibitors of aspartyl protease'20097,608,737'Naphthyl(ethyl)acetamides'20097,592,368'Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors'20097,514,068'Biphenyl-pyrazolecarboxamide compounds'20097,388,017'Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease'20087,321,063'Sulfonamide inhibitors of aspartyl protease'20087,105,546'Acyclic and cyclic amine derivatives'20066,962,996'Inhibitors of p38'20056,878,728'Inhibitors of aspartyl protease'20056,838,474'Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors'20056,759,535'Inhibitors of p38'20046,720,335'Sulfonamide inhibitors of aspartyl protease'20046,617,309'Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease'20036,608,067'Inhibitors of serine proteases, particularly HCV NS3 protease'20036,559,137'Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors'20036,552,019'Inhibitors of p38'20036,436,989'Prodrugs of aspartyl protease inhibitors'20026,392,046'Sulfonamide inhibitors of aspartyl protease'20026,372,778'Sulfonamide inhibitors of aspartyl protease'20026,281,367'Process for the synthesis of HIV protease inhibitors'20016,265,380'Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease'20016,225,350'Butyrate prodrugs derived from lactic acid'20016,127,372'Sulfonamide inhibitors of aspartyl protease'20006,004,957'Sulfonamide inhibitors of aspartyl protease'19995,990,155'Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease'19995,977,137'Sulfonamide inhibitors of aspartyl protease'19995,945,413'Aspartyl protease inhibitors'19995,912,269'Butyrate prodrugs derived from lactic acid'19995,883,123'Butyrate prodrugs derived from lactic acid'19995,883,252'Aspartyl protease inhibitors'19995,880,152'Butyrate prodrugs derived from lactic acid'19995,856,353'Sulfonamide inhibitors of aspartyl protease'19995,783,701'Sulfonamide inhibitors of aspartyl protease'19985,723,490'THF-containing sulfonamide inhibitors of aspartyl protease'19985,693,847'Heteroatom functionalized .alpha.-methyl ketones'19975,691,372'Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease'19975,665,774'Immunosuppressive compounds'19975,622,970'Immunosuppressive compounds'19975,585,397'Sulfonamide inhibitors of aspartyl protease'19965,516,797'Immunosuppressive compounds'19965,330,993'Immunosuppressive compounds'19945,225,528'Cyclic hexapeptide oxytocin antagonists'19935,192,773'Immunosuppressive compounds'1993

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1993–2013Patents assigned to VERTEX PHARMA (43)· patent assignee history
1993–2001Based in Cambridge, MA, US· patent location history
1996–2012Based in Arlington, MA, US· patent location history
2003–2013Based in San Diego, CA, US· patent location history
2003–2009Based in Beverly, MA, US· patent location history
2009–2020Patents assigned to CONCERT PHARMACEUTICALS INC (71)· patent assignee history
2009–2020Based in Lexington, MA, US· patent location history
2012–2015Patents assigned to TUNG ROGER (20)· patent assignee history
2012–2016Patents assigned to TUNG ROGER D (12)· patent assignee history
2012–2015Patents assigned to HARBESON SCOTT L (9)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
CONCERT PHARMACEUTICALS INC712009–2020
VERTEX PHARMA431993–2013
TUNG ROGERself202012–2015
TUNG ROGER Dself122012–2016
HARBESON SCOTT L92012–2015
Locations
LocationPatentsSpan
Lexington, Massachusetts, US762009–2020
Arlington, Massachusetts, US221996–2012
Cambridge, Massachusetts, US101993–2001
San Diego, California, US62003–2013
Beverly, Massachusetts, US62003–2009